🔔 THIS WEBSITE IS FOR SALE — Tools-Based Health Information Site with Great Profit Potential. Contact contact@thelungcancercure.com

Lung Cancer Research: Articles & Explainers

Plain-language explainers on lung cancer biology, biomarkers, treatment categories, and how to read clinical trial research — including guides to our own free Research Progress Tracker tool.

What Is the Lung Cancer Research Progress Tracker? How Our Free Tool Works

2026-06-01

A plain-language explanation of how the free Lung Cancer Research Progress Tracker works, what data it uses, and what it does and doesn't do.

Read More →

How to Read Your Research Momentum Score: A Guide to the Lung Cancer Research Progress Tracker

2026-06-03

How the Research Momentum Score on the Lung Cancer Research Progress Tracker is calculated and what it does and doesn't tell you.

Read More →

Lung Cancer Research Progress Tracker vs. Clinical Trial Matching Services: What's the Difference

2026-06-06

How the free Lung Cancer Research Progress Tracker differs from clinical trial matching services like those offered by patient advocacy nonprofits.

Read More →

What Is Non-Small Cell Lung Cancer (NSCLC)? A Plain-Language Guide

2026-06-01

A plain-language explanation of non-small cell lung cancer (NSCLC), its main subtypes, and how it differs from small cell lung cancer.

Read More →

What Is Small Cell Lung Cancer (SCLC)? Key Facts

2026-06-01

Key facts about small cell lung cancer (SCLC), including how common it is, how it's typically staged, and current research directions.

Read More →

EGFR Mutation in Lung Cancer Explained

2026-06-01

What an EGFR mutation in lung cancer means, why it matters for treatment, and the difference between classical and atypical EGFR mutations.

Read More →

ALK-Positive Lung Cancer: What the Research Shows

2026-06-01

What ALK-positive lung cancer means, how common it is, and what current research shows about this NSCLC subtype.

Read More →

KRAS G12C Mutation in Lung Cancer: From 'Undruggable' to Targetable

2026-06-01

How the KRAS G12C mutation in lung cancer went from being considered undruggable to having FDA-approved targeted therapies.

Read More →

What Is Immunotherapy for Lung Cancer? How It Works

2026-06-01

A plain-language explanation of how immunotherapy for lung cancer works and why it represented a major shift in cancer treatment research.

Read More →

What Is Targeted Therapy for Lung Cancer?

2026-06-01

How targeted therapy for lung cancer works, and how it differs from chemotherapy and immunotherapy.

Read More →

What Are Antibody-Drug Conjugates (ADCs)?

2026-06-01

A plain-language explanation of antibody-drug conjugates (ADCs), a fast-growing category of lung cancer research.

Read More →

What Is a Bispecific Antibody? Explained for Lung Cancer Research

2026-06-01

How bispecific antibodies work in lung cancer research and why they represent a growing treatment category.

Read More →

Understanding PD-L1 Testing in Lung Cancer

2026-06-01

What PD-L1 testing measures in lung cancer, how it's used, and its limitations as a predictor of immunotherapy response.

Read More →

What Is Tumor Mutational Burden (TMB)?

2026-06-01

What tumor mutational burden (TMB) means, how it's measured, and how it relates to immunotherapy response in lung cancer.

Read More →

Lung Cancer in Never-Smokers: What Research Says

2026-06-01

What current research says about lung cancer in never-smokers, including risk factors, biology, and rising incidence trends.

Read More →

Why Is Lung Cancer Rising in Non-Smokers?

2026-06-01

The leading research explanations for why lung cancer rates in non-smokers appear to be rising, including air pollution and radon.

Read More →

Radon and Lung Cancer: What You Should Know

2026-06-01

What radon gas is, how it's linked to lung cancer, and why it's considered a significant risk factor even for non-smokers.

Read More →

Air Pollution and Lung Cancer Risk: The Research

2026-06-01

What current research shows about the link between air pollution, particularly fine particulate matter (PM2.5), and lung cancer risk.

Read More →

Low-Dose CT Screening for Lung Cancer: Who Qualifies?

2026-06-01

How low-dose CT (LDCT) lung cancer screening works, the mortality benefit shown in trials, and general eligibility criteria.

Read More →

Understanding Lung Cancer Stages: I Through IV

2026-06-01

A plain-language guide to how lung cancer stages I through IV are generally defined and why staging matters for research and treatment planning.

Read More →

What Is Neoadjuvant Therapy for Lung Cancer?

2026-06-01

What neoadjuvant therapy means in lung cancer treatment, and why it's an active area of current clinical trial research.

Read More →

What Is Adjuvant Therapy After Lung Cancer Surgery?

2026-06-01

What adjuvant therapy means in lung cancer treatment, and why it's used after surgical removal of a tumor.

Read More →

Liquid Biopsy for Lung Cancer: How It Works

2026-06-01

What liquid biopsy testing is, how it detects circulating tumor DNA, and why it's an active area of lung cancer research.

Read More →

Understanding Clinical Trial Phases (I, II, III, IV)

2026-06-01

A plain-language explanation of what clinical trial phases I through IV mean in cancer research.

Read More →

What Does 'Median Overall Survival' Mean in Cancer Research?

2026-06-01

What median overall survival means as a clinical trial statistic, and how to interpret it responsibly.

Read More →

What Is Progression-Free Survival?

2026-06-01

What progression-free survival (PFS) means as a clinical trial outcome measure and how it differs from overall survival.

Read More →

Understanding Lung Cancer Survival Rate Statistics

2026-06-01

How to interpret lung cancer five-year survival rate statistics, including why they vary so dramatically by stage.

Read More →

What Is a Basket Trial?

2026-06-01

What a 'basket trial' is in cancer research and why this trial design has become more common in lung cancer studies.

Read More →

What Is a Master Protocol Trial? Lung-MAP Explained

2026-06-01

What a master protocol clinical trial is, using Lung-MAP as an example of this collaborative research design in lung cancer.

Read More →

STK11 and KEAP1 Mutations: Why They Matter in Lung Cancer

2026-06-01

What STK11 and KEAP1 mutations are in lung cancer, and why they're associated with weaker immunotherapy response.

Read More →

Squamous vs. Non-Squamous NSCLC: What's the Difference

2026-06-01

The difference between squamous and non-squamous non-small cell lung cancer (NSCLC), and why the distinction matters for treatment planning.

Read More →

Understanding FDA Accelerated Approval for Cancer Drugs

2026-06-01

What the FDA's accelerated approval pathway means for new cancer drugs, and how it differs from standard full approval.

Read More →

What Is Circulating Tumor DNA (ctDNA)?

2026-06-01

What circulating tumor DNA (ctDNA) is, how it's detected, and how it's used in lung cancer research and monitoring.

Read More →

Get New Research Findings by Email

Once a week, we summarize the most significant lung cancer research developments — new trial results, FDA actions, and screening guidance changes — in plain language. Free. No spam. Unsubscribe anytime.

By subscribing you agree to our Privacy Policy. We never sell your email address.